Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis

被引:13
作者
Gao, Jie [1 ]
Chen, Yingying [2 ]
Wu, Pengqiang [2 ,3 ]
Wang, Fujue [2 ,4 ]
Tao, Huan [2 ]
Shen, Qianqing [2 ]
Wang, Shuoting [2 ]
Gong, Shuaige [2 ]
Zhang, Xue [2 ]
Zhou, Zhencang [2 ,5 ]
Song, Xianmin [1 ]
Jia, Yongqian [2 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Hematol, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[3] Southwest Med Univ, Affiliated Hosp, Dept Hematol, Luzhou, Peoples R China
[4] Univ South China, Affiliated Hosp 1, Dept Hematol, Hengyang, Peoples R China
[5] Zunyi Med Univ, Affiliated Hosp 3, Dept Hematol, Zunyi, Guizhou, Peoples R China
关键词
Classic Hodgkin lymphoma; non-cancer-specific death; competing risk analysis; Prognosis; SEER database; DISEASE; ABVD; CHEMOTHERAPY; DOXORUBICIN; MORTALITY; THERAPY; IMPACT; TRIAL; MOPP;
D O I
10.1186/s12885-021-08683-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The improved prognosis of classic Hodgkin lymphoma (cHL) has been accompanied by elevated risks of non-cancer-specific death (non-CSD). The aim of this study was to verify the occurrence of non-CSD and its effect on rates of overall survival among adult patients with cHL. Methods To ensure sufficient follow-up time, we analyzed retrospective data from patients aged >= 20 years with cHL that was diagnosed between 1983 and 2005 in the Surveillance, Epidemiology, and End Results (SEER) database. Logistic regression was applied to analyze the non-CSD occurrence in relation to all factors. Using Fine-Gray's method, we calculated the cumulative incidences of CSD and non-CSD. Stacked cumulative incidence plots and ratio of non-CSD to all causes of death were applied to evaluate the effect of non-CSD on rates of overall survival. Finally, we analyzed long-term mortality through Cox proportional hazard regression analysis and competing risk regression analysis to emphasize a more appropriate model of survival for patients with cHL. Results Among the 18,518 patients included, there were 3768 cases of CSD (20.3%) and 3217 of non-CSD (17.4%). Older age, earlier period, male sex, unmarried status, mixed cellularity (MC) and lymphocyte-depletion (LD) histological subtype, and patients received radiotherapy (RT) only were associated with more non-CSD according to binary logistic analysis. The cumulative incidence of non-CSD exceeded CSD after approximately 280 months follow-up. The most common causes of non-CSDs were cardiovascular disease, subsequent primary neoplasms, infectious diseases, accidents, and suicide. In a Cox proportional hazards model, patients who were black, unmarried, at an advanced stage or underwent chemotherapy (CT) alone were at greater risk of mortality than were white patients, who were married, at an early stage, and underwent combined modality; these populations were also found to be at greater risk for CSD in a competing risk model, but the risk of non-CSD did not differ significantly according to race and marital status, patients with early-stage disease and who underwent RT only were found to be at higher risk of non-CSD instead. Conclusions Lymphoma was the cause of death in most patients who died, but non-CSD was not unusual. Patients with cHL should be monitored closely for signs of cardiovascular disease and malignant tumors. Rates of overall survival of patients were diminished by non-CSD, and a competing risk model was more suitable for establishing the prognosis than was the Cox proportional hazards model.
引用
收藏
页数:11
相关论文
共 33 条
[1]   Marital Status and Survival in Patients With Cancer [J].
Aizer, Ayal A. ;
Chen, Ming-Hui ;
McCarthy, Ellen P. ;
Mendu, Mallika L. ;
Koo, Sophia ;
Wilhite, Tyler J. ;
Graham, Powell L. ;
Choueiri, Toni K. ;
Hoffman, Karen E. ;
Martin, Neil E. ;
Hu, Jim C. ;
Nguyen, Paul L. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) :3869-3876
[2]   Long-term cause-specific mortality of patients treated for Hodgkin's disease [J].
Aleman, BMP ;
van den Belt-Dusebout, AW ;
Klokman, WJ ;
van't Veer, MB ;
Bartelink, H ;
van Leeuwen, FE .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3431-3439
[3]  
ANSELMO AP, 1990, HAEMATOLOGICA, V75, P155
[4]   Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma [J].
Blank, Oliver ;
von Tresckow, Bastian ;
Monsef, Ina ;
Specht, Lena ;
Engert, Andreas ;
Skoetz, Nicole .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (04)
[5]   Hodgkin Lymphoma in Adults [J].
Broeckelmann, Paul J. ;
Eichenauer, Dennis A. ;
Jakob, Tina ;
Follmann, Markus ;
Engert, Andreas ;
Skoetz, Nicole .
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (31-32) :535-+
[6]   Balancing risk and benefit in early-stage classical Hodgkin lymphoma [J].
Broeckelmann, Paul J. ;
Sasse, Stephanie ;
Engert, Andreas .
BLOOD, 2018, 131 (15) :1666-1678
[7]   CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].
CANELLOS, GP ;
ANDERSON, JR ;
PROPERT, KJ ;
NISSEN, N ;
COOPER, MR ;
HENDERSON, ES ;
GREEN, MR ;
GOTTLIEB, A ;
PETERSON, BA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484
[8]   Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial [J].
Duggan, DB ;
Petroni, GR ;
Johnson, JL ;
Glick, JH ;
Fisher, RI ;
Connors, JM ;
Canellos, GP ;
Peterson, BA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :607-614
[9]   The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study [J].
Ebied, Amr ;
Vuong Thanh Huan ;
Makram, Omar Mohamed ;
Sang, To Kim ;
Ghorab, Mohamed ;
Huyen Thi Ngo ;
Iraqi, Ahmed ;
Kamel, Mohamed Gomaa ;
Tran Ngoc Dang ;
Nguyen Lam Vuong ;
Hirayama, Kenji ;
Nguyen Tien Huy .
CANCER MEDICINE, 2018, 7 (04) :953-965
[10]   Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group [J].
Engert, A ;
Schiller, P ;
Josting, A ;
Herrmann, R ;
Koch, P ;
Sieber, M ;
Boissevain, F ;
de Wit, M ;
Mezger, J ;
Dühmke, E ;
Willich, N ;
Müller, RP ;
Schmidt, BF ;
Renner, H ;
Müller-Hermelink, HK ;
Pfistner, B ;
Wolf, J ;
Hasenclever, D ;
Löffler, M ;
Diehl, V .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3601-3608